All 1 tracked stories fall under one category: pharma. Biotech & Pharma Sector is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about CRISPR
All 1 tracked stories fall under one category: pharma. Biotech & Pharma Sector is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. The 5 average consequence score is below the beat benchmark of 6 in the same window. We currently track 1 Biotech story that mention CRISPR, all published on March 12, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering CRISPR. Shared-story counts are live from our verified record — not editorial picks.
New research suggests that species may possess a greater capacity for 'evolutionary rescue' than previously modeled, potentially averting climate-driven mass extinctions. This discovery has profound implications for the pharmaceutical industry's reliance on biodiversity and synthetic biology's efforts to engineer resilient organisms.